Share on LinkedInShare on LinkedIn

ARTICLE · 23 APRIL 2021

New Ban On Reimbursements Affecting Patient Support Programs

As of April 15, 2021, manufacturers, wholesalers and other intermediaries in the drug supply chain are subject to a new prohibition as a result of the enactment ...

CanadaFood, Drugs, Healthcare, Life Sciences

As of April 15, 2021, manufacturers, wholesalers and other intermediaries in the drug supply chain are subject to a new prohibition as a result of the enactment of the Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan1 (the "Regulation"). As its name implies, this Regulation expands on the list of business practices already proscribed by prohibiting the above-mentioned stakeholders from paying or reimbursing anyone covered by the basic prescription drug insurance plan for the price of a medication or supply covered by this plan. Although exceptions are listed in the Regulation, the ban may affect the continuity of existing patient support programs and establish limits that must be considered in the implementation of new programs by pharmaceutical industry stakeholders in Quebec.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from